All Articles

XTEL's new SAP Store integration dissolves the trade-off between deep ERP integration and best-in-class tools, deploying agentic AI to reshape CPG profitability.

With new funding from top VCs, DropGenie is shrinking gene editing to power the next wave of AI-driven drug discovery using precious patient cells.

As private credit pulls back, PropTech firm Gumption expands its tech-driven financing platform to the West Coast, betting on a seasoned expert to succeed.

Polaris appoints Sealed Air CEO Dustin Semach to its board, a move signaling a calculated pivot towards technology and financial rigor in its powersports strategy.

NH is investing millions in a statewide data grid for its schools, translating military precision into an invisible network designed to protect every student.

Chain's new AI agent automates the complex, conversational dance of freight booking. It's a move that promises not to replace brokers, but to redefine their role.

Brunswick Corp. promises 'multi-million-dollar savings' from operational shifts at its Lowell plant. But behind the corporate buzzwords, a community weighs the price of efficiency.

As travelers trade mega-resorts for meaningful moments, Azamara Cruises bets its future on a simple idea: the next big thing is small. Here's the strategy.

In a cooling life science real estate market, a major lease for advanced manufacturing highlights the rise of radiopharmaceuticals and Boston's enduring industrial might.

A new prostate cancer drug is emerging from a powerful alliance. We deconstruct the strategic rationale behind the deal, revealing a model for the future.

A new high-tech distribution center in Italy reveals the strategy for modern market dominance: a fusion of aggressive retail expansion and radical sustainability.

A new Brooklyn platform is blurring the lines between gallery and retail, but its true innovation lies in its connection to a global AI-powered B2B giant.

With a key NSF grant and promising large-animal data, Endure Biotherapeutics' engineered 'native' bacteria may rewrite the playbook for PKU and beyond.

The NYSE owner is betting its financial infrastructure can solve the carbon market's trust problem, turning credits into an institutional asset class.

A single drug receptor could treat cancer, psoriasis, and liver disease. Can-Fite’s new scientific validation boosts its platform, but clinical and financial hurdles loom.

SKS's new Boston Technicurean Center isn't just a showroom; it's a destination. Explore how this partnership is changing how we design, buy, and live.

A new AI platform, born from its founder's own cancer battle, aims to give patients the tools to navigate complex treatments and advocate for their own care.

MapLight's Phase 2 trial for ASD missed its primary goal, but a powerful signal in reducing irritability in teens could reshape its future and offer a safer alternative.

A Chinese AI innovator and a new European biotech just sealed a massive deal. It’s a blueprint for the future of medicine, where technology and strategy unite for patients.

The explosion welding leader is diversifying into weld overlay, a strategic move to offer turnkey solutions for aging industrial assets in harsh environments.